Previous 10 | Next 10 |
Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 284985, entitled, “Combination Immune The...
Enlivex Therapeutics ( NASDAQ: ENLV ) announced Wednesday that the Israeli Ministry of Health (IMOH) greenlighted further patient enrollment to the company’s Phase I/II trial for cell therapy candidate Allocetra in solid tumors following a review by the trial’s safety panel....
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring Board (DSMB) has completed its prespecified d...
Israel-based Enlivex Therapeutics ( NASDAQ: ENLV ) on Wednesday said it had got approval from French and Belgian regulatory agencies to expand its phase two sepsis trial into those countries. ENLV is conducting a mid-stage trial which is evaluating its cell therapy Allocetra in patien...
Nes-Ziona, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) an...
(NewsDirect) Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. The cleared amendments also allow Enlivex to use a newly developed f...
(NewsDirect) Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. Today, there are several potential applications of cell therapies. They can be used in treating infectious and ...
Received frozen-formulation Allocetra™ IND clearance from The U.S. Food And Drug Administration (FDA) for treatment of patients with advanced solid tumors The protocol of the IND includes intravenous administration of frozen-formulation Allocetra™, stand-alone, and in combinatio...
(NewsDirect) On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break through the immune-suppressing tumor microenvironment – a key roadbl...
--News Direct-- On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break through the immune-suppressing tumor microenvironment – a key roa...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...
Ness-Ziona, Israel, June 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on June 25, 2024, at 4:15 p.m...
Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of Allocetra TM into the knee as a “last resort” Three-month data readout showed a significant reduction in pain and a f...